Stocks of the Hour: Mesoblast, Andromeda Metals, Imugene
A snapshot of the stocks on the move, featuring Mesoblast (ASX:MSB), Andromeda Metals (ASX:ADN) and Imugene (ASX:IMU).
Read More
Imugene Limited
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in Phase 1b/2 study for gastric cancer.
It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene’s CD19 oncolytic virus technology and Celularity’s CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Spotlight Videos
Stocks of the Hour: Mesoblast, Andromeda Metals, Imugene
A snapshot of the stocks on the move, featuring Mesoblast (ASX:MSB), Andromeda Metals (ASX:ADN) and Imugene (ASX:IMU).
WATCH VIDEOAll Imugene Limited Content
News
Stocks of the Hour: Namoi Cotton, Imugene, Beston Global Food
A snapshot of the stocks on the move, featuring Namoi Cotton (ASX:NAM), Imugene (ASX:IMU) and Beston Global Food (ASX:BFC).
Read More
Stocks of the Hour: AML3D, Imugene, Loyal Lithium
A snapshot of the stocks on the move, featuring AML3D (ASX:AL3), Imugene (ASX:IMU) and Loyal Lithium (ASX:LLI).
Read More
ASX rallies 0.55% as Energy outperforms
19 Jul 2023 - The Energy sector demonstrated strong growth, with a rally of 1.7%. Ampol (ASX:ALD) experienced a significant surge of 4.4% following robust fuel sale volumes reported for the first half of the financial year 2023. At the closing bell, the S&P/ASX 200 was 0.55 per cent higher at 7,323.70.
Read More
ASX up 0.53% at noon: Woodside reports a 29% decline in revenue
19 Jul 2023 - Woodside Energy (ASX:WPL), reported a 29% decline in revenue for the second quarter, amounting to $US3.1 billion ($4.5 billion). Sales of oil decreased by 4%, with 48.4 million barrels sold, while production experienced a 5% drop to 44.5 million barrels.
Read More
